Effect of ketanserin on sodium nitroprusside requirements, arterial pressure control and heart rate following coronary artery bypass surgery.
In a double-blind, placebo controlled study ketanserin, a serotonin S2 antagonist, was administered to hypertensive patients who had undergone coronary artery bypass surgery. Patients were allocated randomly to receive placebo or ketanserin at an infusion rate of 0.05, 1 or 2 mg kg-1 h-1. Sodium nitroprusside was used as escape medication. Ketanserin reduced the nitroprusside requirements and improved the quality of arterial pressure control in all groups, and this was significant in the low- and high-dose groups. There was a significant decrease in heart rate in the low- and high-dose groups compared with placebo, and no effect in patients who received the medium dose of ketanserin. Ketanserin may be a useful treatment for hypertension following coronary artery surgery as it reduced arterial pressure without reflex tachycardia.
Hodsman
N B
NB
University Department of Anaesthesia, Glasgow Royal Infirmary.
Colvin
J R
JR
Kenny
G N
GN
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D005260:Female; D005292:Ferricyanides / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007650:Ketanserin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside / Q000627:therapeutic use*; D011183:Postoperative Complications
D005292:Ferricyanides; D009599:Nitroprusside; D007650:Ketanserin